Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
N Arakawa,
M Nakamura,
H Aoki,
and
K Hiramori
Second Department of Internal Medicine, Iwate Medical University, Japan.
OBJECTIVES: This study sought to examine whether plasma brain natriuretic peptide levels can predict prognosis after myocardial infarction. BACKGROUND: It has been suggested that concentrations of plasma brain natriuretic peptide reflect left ventricular function. Although the prognosis after myocardial infarction depends on residual left ventricular function, it is not known whether plasma levels of brain natriuretic peptide after the onset of myocardial infarction can be used to predict long-term outcome. METHODS: Plasma brain natriuretic peptide and atrial natriuretic peptide levels as well as invasive hemodynamic variables were measured in 70 patients with acute myocardial infarction (53 men, 17 women; mean age 65 years). Measurements were obtained on admission (mean 6 h after onset) and on day 2 after onset. Mean follow-up period was 18 months. RESULTS: Plasma brain natriuretic peptide levels measured on admission and day 2 correlated significantly with hemodynamic variables, which are influenced by left ventricular function. However, plasma atrial natriuretic peptide levels correlated with none of the hemodynamic variables measured on admission; and of those measured on day 2, plasma atrial natriuretic peptide levels correlated only with left atrial filling pressure. During the follow-up period (mean 18 +/- 7 months), 11 patients died of cardiac causes. By Kaplan-Meier analysis, it was found that patients with plasma brain natriuretic peptide levels higher than the median level, both on admission and on day 2, had significantly higher mortality rates than those with the submedian level (on admission, p < 0.01; on day 2, p < 0.05). However, only the plasma atrial natriuretic peptide level obtained immediately after admission was significantly related to survival (p < 0.01). By Cox proportional hazards model analysis of the noninvasive variables, it was found that plasma brain natriuretic peptide concentration was more closely related to survival after myocardial infarction (p = 0.0001). CONCLUSIONS: Increased plasma brain natriuretic peptide concentrations in the early or subacute phase of myocardial infarction are a powerful noninvasive indicator of poor prognosis, possibly reflecting residual left ventricular function after myocardial infarction.
This article has been cited by other articles:

|
 |

|
 |
 
D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction
Eur. Heart J.,
September 1, 2008;
29(17):
2116 - 2124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Q. Khan, O. Dhillon, D. Kelly, I. B. Squire, J. Struck, P. Quinn, N. G. Morgenthaler, A. Bergmann, J. E. Davies, and L. L. Ng
Plasma N-Terminal B-Type Natriuretic Peptide as an Indicator of Long-Term Survival After Acute Myocardial Infarction: Comparison With Plasma Midregional Pro-Atrial Natriuretic Peptide: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1857 - 1864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. West, P. J. Nestel, A. C. Kirby, R. Schnabel, D. Sullivan, R. J. Simes, C. Pollicino, E. Lubos, T. F. Munzel, H. D. White, et al.
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study
Eur. Heart J.,
April 1, 2008;
29(7):
923 - 931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Q Khan, P Quinn, J E Davies, and L L Ng
N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction
Heart,
January 1, 2008;
94(1):
40 - 43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kempf, E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K. C. Wollert, and L. Wallentin
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction
Eur. Heart J.,
December 1, 2007;
28(23):
2858 - 2865.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A Pascual-Figal, M. J Antolinos, A. Bayes-Genis, T. Casas, F. Nicolas, and M. Valdes
B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans
Heart,
September 1, 2007;
93(9):
1077 - 1080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Ahmed, S. Zafar, A. Y. Alam, N. Ahktar, M. A. Shah, and M. A. Alpert
Plasma Levels of B-Type Natriuretic Peptide in Patients With Unstable Angina Pectoris or Acute Myocardial Infarction: Prognostic Significance and Therapeutic Implications
Angiology,
June 1, 2007;
58(3):
269 - 274.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Circulation,
April 3, 2007;
115(13):
e356 - e375.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Blyth, B. A. Groenning, P. B. Mark, T. N. Martin, J. E. Foster, T. Steedman, J. J. Morton, H. J. Dargie, and A. J. Peacock
NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension
Eur. Respir. J.,
April 1, 2007;
29(4):
737 - 744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Clin. Chem.,
April 1, 2007;
53(4):
552 - 574.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Bjorklund, T Jernberg, P Johanson, P Venge, M Dellborg, L Wallentin, B Lindahl, and the ASSENT-2 and ASSENT-PLUS Study Groups
Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction
Heart,
June 1, 2006;
92(6):
735 - 740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Qian, A. Leung, P. Harding, and M. C. LaPointe
PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK
Am J Physiol Heart Circ Physiol,
May 1, 2006;
290(5):
H1740 - H1746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow, J. A. de Lemos, M. A. Blazing, M. S. Sabatine, S. A. Murphy, P. Jarolim, H. D. White, K. A. A. Fox, R. M. Califf, E. Braunwald, et al.
Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease
JAMA,
December 14, 2005;
294(22):
2866 - 2871.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Brueckmann, G. Huhle, S. Lang, K. K. Haase, T. Bertsch, C. Weiss, J. J. Kaden, C. Putensen, M. Borggrefe, and U. Hoffmann
Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis
Circulation,
July 26, 2005;
112(4):
527 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Jarai, N. Iordanova, R. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyongyosi, G. Geyer, J. Wojta, and K. Huber
Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide
Eur. Heart J.,
February 1, 2005;
26(3):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schnabel, H. J. Rupprecht, K. J. Lackner, E. Lubos, C. Bickel, J. Meyer, T. Munzel, F. Cambien, L. Tiret, S. Blankenberg, et al.
Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study
Eur. Heart J.,
February 1, 2005;
26(3):
241 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bassan, A. Potsch, A. Maisel, B. Tura, H. Villacorta, M. V. Nogueira, A. Campos, R. Gamarski, A. C. Masetto, and M. A. Moutinho
B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation
Eur. Heart J.,
February 1, 2005;
26(3):
234 - 240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-R. Blom, A. W.J. van 't Hof, J. P.S. Henriques, J. H. Geertman, R. Slingerland, and J. C.A. Hoorntje
NT-proBNP: a marker for successful myocardial reperfusion in AMI patients treated with primary percutaneous coronary intervention
Eur J Heart Fail,
October 1, 2004;
6(6):
749 - 752.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, S. D. Anker, et al.
Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial
Circulation,
September 28, 2004;
110(13):
1780 - 1786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Suzuki, M. Yoshimura, M. Nakayama, Y. Mizuno, E. Harada, T. Ito, S. Nakamura, K. Abe, M. Yamamuro, T. Sakamoto, et al.
Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction: A Long-Term Follow-Up Analysis
Circulation,
September 14, 2004;
110(11):
1387 - 1391.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sadanandan, C. P. Cannon, K. Chekuri, S. A. Murphy, P. M. DiBattiste, D. A. Morrow, J. A. de Lemos, E. Braunwald, and C. M. Gibson
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction
J. Am. Coll. Cardiol.,
August 4, 2004;
44(3):
564 - 568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. A. Murphy, N. Rifai, C. M. Gibson, E. M. Antman, and E. Braunwald
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy
J. Am. Coll. Cardiol.,
July 21, 2004;
44(2):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sharp and J. Mayet
Review: The utility of BNP in clinical practice
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2004;
5(2):
53 - 58.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Goetze, W. Yongzhong, J. F Rehfeld, E. Jorgensen, and J. Kastrup
Coronary angiography transiently increases plasma pro-B-type natriuretic peptide
Eur. Heart J.,
May 1, 2004;
25(9):
759 - 764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, J. Trawinski, et al.
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy
Eur J Heart Fail,
March 15, 2004;
6(3):
343 - 350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Tapanainen, K. S. Lindgren, T. H. Makikallio, O. Vuolteenaho, J. Leppaluoto, and H. V. Huikuri
Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era
J. Am. Coll. Cardiol.,
March 3, 2004;
43(5):
757 - 763.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Logeart, G. Thabut, P. Jourdain, C. Chavelas, P. Beyne, F. Beauvais, E. Bouvier, and A. C. Solal
Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure
J. Am. Coll. Cardiol.,
February 18, 2004;
43(4):
635 - 641.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. de Denus, C. Pharand, and D. R. Williamson
Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
Chest,
February 1, 2004;
125(2):
652 - 668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Berendes, C. Schmidt, H. Van Aken, M. G. Hartlage, M. Rothenburger, S. Wirtz, H. H. Scheld, G. Brodner, and M. Walter
A-Type and B-Type Natriuretic Peptides in Cardiac Surgical Procedures
Anesth. Analg.,
January 1, 2004;
98(1):
11 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Clerico and M. Emdin
Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review
Clin. Chem.,
January 1, 2004;
50(1):
33 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Vourvouri, A. F.L. Schinkel, J. R.T.C. Roelandt, F. Boomsma, G. Sianos, M. Bountioukos, F. B. Sozzi, V. Rizzello, J. J. Bax, H. I. Karvounis, et al.
Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device
Eur J Heart Fail,
December 1, 2003;
5(6):
767 - 774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. Frampton, J. Turner, I. G. Crozier, and T. G. Yandle
B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction
Circulation,
June 10, 2003;
107(22):
2786 - 2792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ruskoaho
Cardiac Hormones as Diagnostic Tools in Heart Failure
Endocr. Rev.,
June 1, 2003;
24(3):
341 - 356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. A. Murphy, L. A. Demopoulos, P. M. DiBattiste, C. H. McCabe, C. M. Gibson, C. P. Cannon, and E. Braunwald
Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
J. Am. Coll. Cardiol.,
April 16, 2003;
41(8):
1264 - 1272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Omland, A. Persson, L. Ng, R. O'Brien, T. Karlsson, J. Herlitz, M. Hartford, and K. Caidahl
N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes
Circulation,
December 3, 2002;
106(23):
2913 - 2918.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. LaPointe, X.-P. Yang, O. A. Carretero, and Q. He
Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector
Am J Physiol Heart Circ Physiol,
October 1, 2002;
283(4):
H1439 - H1445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Nakamura, H Endo, M Nasu, N Arakawa, T Segawa, and K Hiramori
Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population
Heart,
February 1, 2002;
87(2):
131 - 135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Braunschweig, C. Linde, M.J. Eriksson, C. Hofman-Bang, and L. Ryden
Continous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure
Eur. Heart J.,
January 1, 2002;
23(1):
59 - 69.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J G Crilley and M Farrer
Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction
Heart,
December 1, 2001;
86(6):
638 - 642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. de Lemos, D. A. Morrow, J. H. Bentley, T. Omland, M. S. Sabatine, C. H. McCabe, C. Hall, C. P. Cannon, and E. Braunwald
The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes
N. Engl. J. Med.,
October 4, 2001;
345(14):
1014 - 1021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Richards, R. Doughty, M. G. Nicholls, S. MacMahon, N. Sharpe, J. Murphy, E. A. Espiner, C. Frampton, T. G. Yandle, and for the Australia-New Zealand Heart Failure Group
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
J. Am. Coll. Cardiol.,
June 1, 2001;
37(7):
1781 - 1787.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. He, D. Wang, X.-P. Yang, O. A. Carretero, and M. C. LaPointe
Inducible regulation of human brain natriuretic peptide promoter in transgenic mice
Am J Physiol Heart Circ Physiol,
January 1, 2001;
280(1):
H368 - H376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Frey, R. Pacher, G. Locker, A. Bojic, E. Hartter, W. Woloszczuk, and B. Stanek
Prognostic Value of Hemodynamic vs Big Endothelin Measurements During Long-term IV Therapy in Advanced Heart Failure Patients
Chest,
June 1, 2000;
117(6):
1713 - 1719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. He, G. Wu, and M. C. Lapointe
Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac
Am J Physiol Endocrinol Metab,
June 1, 2000;
278(6):
E1115 - E1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Langenickel, I. Pagel, K. Hohnel, R. Dietz, and R. Willenbrock
Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure
Am J Physiol Heart Circ Physiol,
May 1, 2000;
278(5):
H1500 - H1506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Rademaker, V. A. Cameron, C. J. Charles, E. A. Espiner, M. G. Nicholls, C. J. Pemberton, and A. M. Richards
Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction
Am J Physiol Heart Circ Physiol,
March 1, 2000;
278(3):
H731 - H740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. He and M. C. LaPointe
Interleukin-1{beta} Regulates the Human Brain Natriuretic Peptide Promoter via Ca2+-Dependent Protein Kinase Pathways
Hypertension,
January 1, 2000;
35(1):
292 - 296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, and T. G. Yandle
Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction
Circulation,
February 16, 1999;
99(6):
786 - 792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A M Richards, M G Nicholls, T G Yandle, H Ikram, E A Espiner, J G Turner, R C Buttimore, J G Lainchbury, J M Elliott, C Frampton, et al.
Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
Heart,
February 1, 1999;
81(2):
114 - 120.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
I. Rubinstein and F. D. Hong
Circulating Natriuretic Peptides : A Biologic Marker of Tissue Injury?
Chest,
January 1, 1999;
115(1):
7 - 8.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. He and M. C. LaPointe
Interleukin-1ß Regulation of the Human Brain Natriuretic Peptide Promoter Involves Ras-, Rac-, and p38 Kinase–Dependent Pathways in Cardiac Myocytes
Hypertension,
January 1, 1999;
33(1):
283 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Richards, M. G. Nicholls, T. G. Yandle, C. Frampton, E. A. Espiner, J. G. Turner, R. C. Buttimore, J. G. Lainchbury, J. M. Elliott, H. Ikram, et al.
Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin : New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction
Circulation,
May 19, 1998;
97(19):
1921 - 1929.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R Murdoch, J. Byrne, J. J Morton, T. A McDonagh, S. D Robb, S. Clements, I. Ford, J. J V McMurray, and H. J Dargie
Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice
Heart,
December 1, 1997;
78(6):
594 - 597.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|